Gilead Archives

News and Trends 25 Aug 2016

Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

After losing AbbVie as a partner, Galapagos has pressed on with Gilead in the development of filgotinib for rheumatoid arthritis. Phase III trials have officially begun! Galapagos is making progress as its rheumatoid arthritis drug, filgotinib, enters Phase III clinical trials. This comes after a major setback when its deal with AbbVie fell through last fall. It’s not […]

August 25, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 24 Aug 2016

While working on its HIV Cure, Gilead gives Europe an ‘HIV Vaccine’

Despite progress in HIV treatments and towards an HIV cure, the infection rate has risen to unprecedented levels in Europe. Gilead’s HIV-1 ‘vaccine’, Truvada, has just been approved for marketing in Europe to stop its spread. The year 2014 brought the highest number of new HIV diagnoses ever recorded in Europe, 94% of which were […]

August 24, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 15 Aug 2016

Gilead licenses Danish Bispecific antibodies for the next HIV Cure

As an add-on to their previously secretive partnership, Genmab is now licensing its bispecific antibodies for Gilead‘s pursuit of an HIV cure for as much as €248M. At the top of the Pyramid of European Biotech value, Genmab is one of the success stories in Copenhagen’s Biotech ecosystem. Its technology for innovative antibodies has allowed it […]

August 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

gilead hiv aids grant retroviral truvada

News and Trends 23 Feb 2016

How could the HIV Field benefit from Gilead’s new €2M Research Grants?

The US Giant Gilead is opening a new program of Grants to fund the next generation of HIV research for 3-years. Targets are academic institutions and non-profit organization. HIV remains a global health challenge, with around 37 million people infected in the world. The rate of new infections fell in the last decades, but it is […]

February 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

abbvie galapagos cystic fibrosis glpg1837

News and Trends 17 Feb 2016

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

Galapagos (Belgium) is moving forward with their cystic fibrosis drug candidate after promising Phase I results – and still in collaboration with AbbVie (US). Curiouser and curiouser… Galapagos is one of the most hotly-discussed Biotechs in Europe, with around 400 employees and historic IPOs on NASDAQ. It is partnered with several big Pharma, like Gilead, AbbVie, Servier (to develop […]

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

Gilead galapagos abbvie filgotinib partner rheumatoid

News and Trends 18 Dec 2015

Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal

At last! We now know the fate of Galapagos Phase III Rheumatoid Arthritis drug after AbbVie‘s shocking abandonment. The Mystery replacement partner has now been revealed as Gilead! Galapagos will receive an upfront payment of €670M from California’s Gilead, consisting of a license fee of €277M and a €393M equity investment in Galapagos. In addition, […]

December 18, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Nov 2015

A Group of French Medics are Questioning the Fastest-Growing Big Biotech in the World…

Approved drugs can always show bad signs once injected massively. Four physicians from Paris sent a letter to the New England Journal of Medicine to report that Gilead’s Hepatitis C blockbuster drug, Sovaldi, can cause abnormally slower heart rates and risks of Heart Failure… The French Physicians report used data based on 415 patients treated […]

November 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Jul 2015

After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO

Two weeks ago, I travelled through Denmark to interview 15 CEOs to film its biotech industry, Labiotech Tour Denmark. Amongst them was Martin Bonde, CEO of Dansk Biotech and former CEO of Epitherapeutics which was sold at €60M to Gilead (the 2nd largest Biotech in the world). I just read he is switching to Vaccibody the Norwegian Biotech and […]

July 6, 2015 - 1 minutemin - By Philip Hemme

News and Trends 19 May 2015

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Does NASH mean anything to you? You should be vigilant about this market as it could be the source of next major blockbusters. This new and latest acquisition by Boehringer, is yet another sign of the growing interest for NASH treatments, already chased by companies such as Intercept, Genfit or Gilead. NASH, or non-alcoholic steatohepatitis, is regarded as […]

May 19, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 7 May 2015

Gilead acquired epigenetics-expert EpiTherapeutics

Gilead Sciences has acquired the small Danish biotech EpiTherapeutics for €57M. The epigenetics-expert has generated a library of small molecule inhibitors of gene transcription regulation than can be used for certain cancer treatments. The American company announced the signing of a definitive agreement to purchase the Danish company for €57M. EpiTherapeutics is developing innovative cancer […]

May 7, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 1 Feb 2015

Phenex sells out its main programme to Gilead

Gilead Sciences announces the acquisition of Phenex Pharmaceuticals’ development program for non-alcoholic steatohepatitis (NASH) and other liver diseases. Gilead Sciences and Phenex Pharmaceuticals announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including non-alcoholic steatohepatitis […]

February 1, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 10 Oct 2014

How Gilead’s Hepatitis C Treatment challenges European Public Health Systems

American Biotech company Gilead is selling its new drug Sovaldi since 2013, which brings significant breakthrough in Hepatitis C treatment. The high cost of the drug, up to €100 000, is a challenge for european Public Health system which tries to lower its overall cost for their public health system. Hepatitis C is an infectious disease […]

October 10, 2014 - 3 minutesmins - By Philip Hemme

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Gilead

Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

While working on its HIV Cure, Gilead gives Europe an ‘HIV Vaccine’

Gilead licenses Danish Bispecific antibodies for the next HIV Cure

How could the HIV Field benefit from Gilead’s new €2M Research Grants?

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal

A Group of French Medics are Questioning the Fastest-Growing Big Biotech in the World…

After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Gilead acquired epigenetics-expert EpiTherapeutics

Phenex sells out its main programme to Gilead

How Gilead’s Hepatitis C Treatment challenges European Public Health Systems

Subscribe to our newsletter to get the latest biotech news!

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!